Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Schreier, Verena Natalie ^a   Petho, Lilla ^a,b   Orbán, Erika ^b,d   Marquardt, Andreas ^a   Petre, Brindusa Alina ^c   Mezo, Gábor ^b   Manea, Marilena ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CHAPERONE; DAUNORUBICIN; FATTY ACID BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEAT SHOCK PROTEIN 70; PROTEIN DISULFIDE ISOMERASE; PYROGLUTAMIC ACID HISTIDYLTRYPTOPHANYLLYSINE(ACETYL) HISTIDYLASPARTYLTRYPTOPHANYLLYSINE (DAUNORUBICIN AMINOOXYACETYL) PROLYLGLYCINE AMIDE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE; CYTOTOXIN; GNRH-III, ACETYLLYSYL(4)-(DAUNORUBICIN-AMINOOXYACETYL)LYSYL(8)-; GONADORELIN; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; LIVER; RAT; SYNTHESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOTOXINS; DAUNORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HT29 CELLS; HUMANS; LIVER; LYSOSOMES; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; RATS;

EID: 84899415330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094041     Document Type: Article

References (37)

1. Nagy A, Schally AV (2005) Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des 11: 1167-1180. (Pubitemid 40403375)
2. Mezo{combining double acute accent} G, Manea M (2010) Receptor-mediated tumor targeting based on peptide hormones Expert Opin Drug Deliv 7: 79-96.
3. Majumdar S, Siahaan TJ (2012) Peptide-mediated targeted drug delivery. Med Res Rev 32: 637-658.
4. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 33: 784-811.
5. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, et al. (2000) Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17: 1063-1069.
6. Engel J, Emons G, Pinski J, Schally AV (2012) AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 21: 891-899.
7. Lovas S, Pályi I, Vincze B, Horváth J, Kovács M, et al. (1998) Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 52: 384-389. (Pubitemid 29018332)
8. Kovács M, Sepro{combining double acute accent}di J, Koppán M, Horváth JE, Vincze B, et al. (2002) Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats, J Neuroendocrinol 14: 647-655.
9. Manea M, Mezo{combining double acute accent} G (2013) lGnRH-III - a promising candidate for anticancer drug development. Protein Pept Lett 20: 439-449.
10. Orbán E, Mezo{combining double acute accent} G, Schlage P, Csík G, Kulić Z, et al. (2011) In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 41: 469-483.
11. Schlage P, Mezo{combining double acute accent} G, Orbán E, Bo{combining double acute accent}sze S, Manea M (2011) Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J Control Release 156: 170-178.
12. Manea M, Tóvári J, Tejeda M, Schulcz A, Kapuvári B, et al. (2012) In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. Anticancer Drugs 23: 90-97.
13. Manea M, Leurs U, Orbán E, Baranyai Z, Öhlschläger P, et al. (2011) Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4. Bioconjug Chem 22: 1320-1329.
14. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, et al. (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33: 1083-1096. (Pubitemid 41043749)
15. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
16. Orbán E, Manea M, Marquadt A, Bánóczi Z, Csík G, et al. (2011) A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro. Bioconjug Chem 22: 2154-2165.
17. Sarto C, Binz PA, Mocarelli P (2000) Heat shock proteins in human cancer. Electrophoresis 21: 1218-1226. (Pubitemid 30230786)
18. Musch MW, Kaplan B, Chang EB (2001) Role of Increased Basal Expression of Heat Shock Protein 72 in Colonic Epithelial c2BBE Adenocarcinoma Cells. Cell Growth and Differentiation 12: 419-426. (Pubitemid 32762691)
19. Grivicich I, Regner A, Zanoni C, Correa LP, Jotz GP, et al. (2007) Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis 22: 1201-1208. (Pubitemid 47304789)
20. Goloudina AR, Demidov ON, Garrido C (2012) Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 325: 117-124.
21. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, et al. (2013) A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 11: 219-229.
22. Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, et al. (2007) Anticancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 14: 2839-2847. (Pubitemid 350201651)
23. Zamanian M, Veerakumarasivam A, Abdullah S, Rosli R (2013) Calreticulin and Cancer. Pathol Oncol Res 19: 149-154.
24. Ataman-Onal Y, Beaulieu C, Busseret S, Charrier J-P, Choquet-Kastylevsky G, et al. (2011) Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer. US20110104701 A1.
25. Zhong S, Ye W, Lin SH, Liu JY, Leong J, et al. (2011) Zeranol induces cell proliferation and protein disulfide isomerase expression in mammary gland of ACI rat. Anticancer Res 31: 1659-1665.
26. Goplen D, Wang J, Enger PØ, Tysnes BB, Terzis AJ, et al. (2006) Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 66: 9895-9902. (Pubitemid 44672041)
27. Egger S, Chaikuad A, Kavanagh KL, Oppermann U, Nidetzky B (2010) UDP-glucose dehydrogenase: structure and function of a potential drug target. Biochem Soc Trans 38: 1378-1385.
28. Wang TP, Pan YR, Fu CY, Chang HY (2010) Down-regulation of UDP-glucose dehydrogenase affects glycosaminoglycans synthesis and motility in HCT-8 colorectal carcinoma cells. Exp Cell Res 316: 2893-2902.
29. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, et al. (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342-347. (Pubitemid 28047077)
30. Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489-503. (Pubitemid 351767117)
31. Junqin L, Qing L, Xiaodong W, Huijun Y, Hua L (2012) The study of fatty acid binding protein expression in human breast cancer tissue and its significance. J Biosci Med 2: 1.
32. Li Z, Huang C, Bai S, Pan X, Zhou R, et al. (2008) Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer 123: 2377-2383.
33. Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D, et al. (1999) Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 20: 2952-2960. (Pubitemid 29517227)
34. Nagai M, Yoneda Y (2012) Small GTPase Ran and Ran-binding proteins. BioMol Concepts 3: 307-318.
35. Rensen WM, Roscioli E, Tedeschi A, Mangiacasale R, Ciciarello M, et al. (2009) RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner. Oncogene 28: 1748-1758.
36. Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, et al. (2010) RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 123: 375-386.
37. Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ (2000) RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J 14: 2549-2558.